A suspected case of COVID-19 vaccine (Covishield) induced Guillain Barre syndrome-a case report


  • Anirudh Gupta Department of Medicine, LLRM Medical College, Meerut, Uttar Pradesh, India
  • S. L. Verma Department of Medicine, LLRM Medical College, Meerut, Uttar Pradesh, India
  • Dinesh Rana Department of Medicine, LLRM Medical College, Meerut, Uttar Pradesh, India
  • Varnik Goel LLRM Medical College, Meerut, Uttar Pradesh, India




Covishield, COVID vaccination, GBS, Polyneuropathy


Guillain Barre syndrome (GBS) is a collection of clinical syndromes that manifest as an acute inflammatory poly radiculopathy. It usually presents as an acute, non-febrile, monophonic, post infectious illness manifesting as ascending weakness and areflexia. It is an autoimmune disorder characterized by production of antibodies against the myelin and is often triggered by bacterial and viral infections, vaccines against rabies, flu and COVID-19. Here we present a case of 31 years old male with characteristic signs and symptoms of GBS possibly triggered by Covishield vaccine.

Author Biography

Anirudh Gupta, Department of Medicine, LLRM Medical College, Meerut, Uttar Pradesh, India

Junior Resident, Department of Medicine, LLRM Medical College, Meerut


Silvery A, Gali JH, Thomas V, Roohen S. A study on Adverse Effects Following Immunization (AEFI) following Covishield Vaccination among Health Care Workers at Tertiary Health Care centre. Int J Health Clin Res. 2021;4(14):284-9.

Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K et al. Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374:n1931.

Kaur U, Ojha B, Pathak BK, Singh A, Giri KR, Singh A et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinicalMedicine. 2021;38:101038.

Kamal D, Thakur V, Nath N, Malhotra T, Gupta A, Batlish R. Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study. Med J Armed Forces India. 2021;77(2):S283.

Vellozzi C, Iqbal S, Broder K. Guillain-Barré syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis. 2014;58(8):1149-55.

Nasuelli NA, De Marchi F, Cecchin M, De Paoli I, Onorato S, Pettinaroli R et al. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. Neurol Sci. 2021;17:1-3.

Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Rep. 2021;14:e243629.

Finsterer J. Exacerbating Guillain-Barré syndrome eight days after vector-based COVID-19 vaccination. Case Rep Infect Dis. 2021;2021:3619131.

Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA et al. Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann Neurol. 2021;90(2):312-4.

COVID-19 Vaccination Status. Co-Win Statistics. Available at: cowin.gov.in. Accessed on 20th December 2021.

Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13:e13426.






Case Reports